📊 Market Recap As of the October 10, 2026 session, 'MRNA' closed at $225.00, soaring +14.21% with an intraday amplitude of 14.13%. The stock printed a fresh 52-week high at $225.00, marking a decisive breakout from the prior resistance near $199.83. Volume reached 28.82 million shares with a volume ratio of 1.43, confirming strong institutional conviction behind the move. 🚀 Key Drivers NIH Cancer Vaccine Initiative: The New York Times reported that the NIH is accelerating a public-private partnership to develop cancer vaccines, triggering a sector-wide rally in vaccine developers. ESMO Data Catalyst: Moderna's personalized mRNA cancer vaccine intismeran autogene has three abstracts accepted at ESMO, including Phase 3 INTerpath-001 results for melanoma, with full data expected on October 24

📊 Market Recap As of October 8, 2026, 'Moderna, Inc.' (MRNA) closed at $196.48, up +4.81% with an intraday range of $182.50 - $197.69. The stock is now within roughly 7.4% of its 52-week high of $212.22, extending a powerful rally driven by personalized mRNA cancer vaccine data. After-hours trading pushed the price to $195.79, confirming sustained bullish momentum into the next session. 🚀 Key Drivers Cancer Vaccine Catalyst: Phase 3 INTerpath-001 data for intismeran autogene (with Merck's Keytruda) continues to anchor sentiment, with full melanoma results expected on October 24. ESMO Abstracts Accepted: Three abstracts covering melanoma, pancreatic cancer, and early-stage NSCLC were accepted for the European Society for Medical Oncology congress, broadening the pipeline narrative. Analyst

📊 Market Recap On October 7, 2026 (ET), 'Moderna, Inc.' closed at $187.46, down -7.75% from the prior close of $203.21. The stock hit an intraday high of $212.22, which marked a new 52-week high, before reversing sharply to a low of $186.64. The close is now about 11.7% below that 52-week high, reflecting intense profit-taking after the recent parabolic rally driven by the personalized mRNA cancer vaccine pipeline. 🚀 Key Drivers Cancer Vaccine Data Momentum: Three abstracts on intismeran autogene were accepted for ESMO, including Phase 3 INTerpath-001 melanoma data; full results are expected on October 24. Rally Overextension: The stock has risen more than 5x year-to-date and more than 100% in the past month, leaving it vulnerable to sharp mean-reversion moves. Short-Selling Pressure: Shor

📊 Market Recap Moderna, Inc. ('MRNA') closed at $203.21 on October 6, soaring +6.95% with a trading range of $185.90–$205.77. The stock now sits just 2.7% below its 52-week high of $208.90, showing exceptional relative strength driven by the personalized mRNA cancer vaccine narrative. 🚀 Key Drivers ESMO Catalyst Ahead: Three abstracts for intismeran autogene were accepted by ESMO, with full Phase 3 INTerpath-001 melanoma data expected on October 24. Phase 3 Clinical Momentum: Positive INTerpath-001 results from the Moderna–Merck Keytruda combination continue to fuel institutional repositioning. Macro Risk-On Tone: Broader biotech strength and mRNA-sector enthusiasm lifted peers such as CanSino, reinforcing speculative demand for 'MRNA'. 🎯 Price Outlook Short-Term Upside/Downside Probabilit

📊 Market Recap As of October 3, 2026, 'Moderna, Inc.' (MRNA) closed at $190.01, up +0.57% on the day. The stock is consolidating near the upper end of its explosive range, sitting approximately 9% below its 52-week high of $208.90. After a remarkable run driven by oncology pipeline momentum, the price is now digesting gains while maintaining a bullish structure above the key $183 intraday low. 🚀 Key Drivers Cancer Vaccine Catalyst: The personalized mRNA cancer vaccine intismeran autogene continues to anchor investor enthusiasm, with ESMO presentations and Phase 3 INTerpath-001 data keeping MRNA in the biotech spotlight. Strong Capital Inflows: Five-day capital flow data shows persistent net buying, with October 1 recording a notable inflow of 49.16 million units, suggesting institutional a

📊 Market Recap US Eastern Time on October 2, Moderna, Inc. (MRNA) closed at $188.94, down -1.89% from the previous close of $192.57. The stock touched a daily high of $201.00 before pulling back, and now sits about 9.6% below its 52-week high of $208.90. Trading volume reached 15.40 million shares with a volume ratio of 0.99, suggesting a consolidation phase after a massive rally driven by personalized mRNA cancer vaccine momentum. 🚀 Key Drivers Cancer Vaccine Catalyst: Positive Phase 3 INTerpath-001 results for intismeran autogene, co-developed with Merck's Keytruda, have fueled a more than 100% rally over the past month. ESMO Data Ahead: Three abstracts on intismeran autogene have been accepted by ESMO, with full Phase 3 melanoma results expected on October 24, keeping investor attention

📊 Market Recap As of the latest close on October 1, 'Moderna, Inc.' (MRNA) settled at $192.57, down -5.35% from the prior session. The stock opened at $186.55, touched a high of $196.83 and a low of $184.58, with amplitude of 6.02%. The pullback leaves the price roughly 7.8% below its 52-week high of $208.90. 🚀 Key Drivers Personalized Cancer Vaccine Catalyst: Three abstracts on intismeran autogene were accepted for ESMO, including pivotal 3-phase INTerpath-001 data for melanoma, pancreatic cancer, and early-stage non-small cell lung cancer. Profit-Taking After Parabolic Run: Following a single-day surge of over 12% previously and a year-to-date gain exceeding 500%, momentum traders locked in gains, reflected by a short volume ratio near 19% on recent sessions. Valuation Concerns Against N

📊 Market Recap As of the latest close, 'Moderna, Inc.' (MRNA) traded at $203.46, up +3.13% with a daily gain of $6.18. The stock opened at $197.78, reached an intraday high of $208.90 and a low of $190.00, with amplitude of 9.58%. The close sits just 2.6% below its 52-week high of $208.90, underscoring an intact breakout structure supported by personalized mRNA cancer vaccine momentum. 🚀 Key Drivers Cancer Vaccine Catalyst: The personalized mRNA cancer vaccine intismeran autogene, co-developed with Merck's Keytruda, continues to anchor the bullish narrative after recent Phase 3 INTerpath-001 success. ESMO Data Spotlight: Three abstracts on intismeran autogene were accepted by the European Society for Medical Oncology, covering melanoma, pancreatic cancer, and early-stage non-small cell lun

📊 Market Recap As of the latest close on September 29, 2026, 'Moderna, Inc. (MRNA)' settled at $197.28, down a modest -0.80%. The stock is consolidating just below its 52-week high of $202.67, holding a strong year-to-date gain of over 5x as the market continues to price in the long-term potential of its personalized mRNA cancer vaccine platform. The current price action remains firmly bullish, with the stock trading above all major moving averages. Despite the slight pullback, the broader trend remains intact as investors position ahead of the highly anticipated ESMO data presentations and the complete Phase 3 melanoma results expected on October 24. 🚀 Key Drivers Personalized Cancer Vaccine Momentum: The company's personalized mRNA cancer vaccine, intismeran autogene, has become the cent

📊 Market Recap As of the latest US session close, 'Moderna, Inc. (MRNA)' settled at $198.88, rising $4.06 or +2.08%. The stock touched a new 52-week high of $202.67 intraday, reflecting powerful upside momentum driven by the personalized mRNA cancer vaccine narrative. Pre-market activity near $196.42 and after-hours strength near $198.25 point to persistent investor interest, placing MRNA firmly in a high-velocity breakout regime. 🚀 Key Drivers Cancer Vaccine Catalyst: Three abstracts for intismeran autogene have been accepted for the European Society for Medical Oncology meeting, with the pivotal Phase 3 INTerpath-001 melanoma data scheduled for October 24. Regulatory and Analyst Momentum: Following a positive Phase 3 readout with Merck's Keytruda, Argus Research upgraded MRNA to Buy with